Comparative Pharmacology
Head-to-head clinical analysis: HUMALOG PEN versus NOVOLOG INNOLET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMALOG PEN versus NOVOLOG INNOLET.
HUMALOG PEN vs NOVOLOG INNOLET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin lispro is a rapid-acting insulin analog that binds to the insulin receptor, activating tyrosine kinase activity and downstream signaling pathways (e.g., PI3K/Akt) to promote glucose uptake in skeletal muscle and adipose tissue, inhibit hepatic gluconeogenesis, and regulate lipid and protein metabolism.
Insulin aspart is a rapid-acting insulin analog that lowers blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. It binds to the insulin receptor, activating tyrosine kinase activity, which leads to glucose transporter translocation and metabolic effects.
Subcutaneously 0.5–1 unit/kg/day divided into multiple doses (usually 3 or more), administered 15 minutes before or immediately after meals.
Subcutaneous injection, 0.5-1.0 unit/kg/day in divided doses, with meals.
None Documented
None Documented
Approximately 0.5-1 hour (rapid; subcutaneous absorption rate-limited).
Terminal half-life: 81 minutes (range 70–90 minutes) for subcutaneous administration; reflects absorption-rate limited elimination
Renal: 60-80% of dose excreted as metabolites; remainder hepatobiliary and fecal.
Renal: approximately 30% of total clearance as unchanged drug; hepatobiliary/fecal: minor (less than 1%)
Category C
Category C
Insulin Analog
Insulin Analog